New Research Collaboration Will Boost Search for Low Molecular Weight Drugs

A collaborative agreement between American and Danish biopharmaceutical companies is expected to advance the discovery of new low molecular weight drugs.

Nuevolution A/S (Copenhagen, Denmark) has announced that it has entered into a collaborative agreement with Janssen Biotech, Inc. (Horsham, PA, USA). Janssen is a subsidiary of the international medical devices, pharmaceutical, and consumer packaged goods manufacturer Johnson & Johnson (New Brunswick, NJ, USA).

The collaboration is intended to generate new low molecular weight drugs by exploiting Nuevolution’s proprietary Chemetics drug discovery platform. Chemetics is a unique, patent protected drug discovery platform for both identification and optimization of hit to drug candidates. It is a hybrid of proven wet chemistry and molecular biology that enables DNA encoded synthesis of billions of chemically diverse drug-like small molecule compounds, and the efficient screening and optimization of these, facilitating effective identification of drug candidates at an unprecedented speed and scale.

Within the framework of the collaboration, Nuevolution will apply its Chemetics platform to discover and advance drug candidates against drug targets of interest to Janssen. Under the terms of the agreement, Nuevolution will receive an upfront payment, research funding, and would be eligible to milestone payments upon achievement of specified research, development, and commercial milestones. In addition, Nuevolution would be entitled to receive certain royalty payments on net-sale of products that may be commercialized as a result of the collaboration.

“We are excited about entering into the extensive collaboration with Janssen,” said Alex Gouliaev, CEO of Nuevolution A/S. “We are looking forward to an excellent working relationship with their dedicated research and development teams.”

Related Links:
Nuevolution A/S
Janssen Biotech, Inc.
Johnson & Johnson